Increased expression of ?5?1-integrin is a prognostic marker for patients with gastric cancer

• Autores: J. Ren, Chuang Guo
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 16, Nº. 7, 2014, págs. 668-674
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective The study was to evaluate the association of expression level of ?5?1-integrin with clinicopathologic features and prognosis in gastric cancer (GC).

    Methods The expression of ?5?1-integrin in normal gastric mucosa and GC tissue was detected with immunohistochemistry. The level of ?5 and ?1 mRNA in GC tissues and non-neoplastic tissues was evaluated in 48 paired cases by quantitative real-time polymerase chain reaction (qRT-PCR). Survival analysis by the Kaplan�Meier method was performed to assess prognostic significance.

    Results The ?5?1-integrin expression was detected in 68.3 % (127/186) GC samples, and there was a significant difference on their positive expression rate between GC tissue and normal gastric mucosa (P < 0.001). The positive expression rate of ?5?1-integrin in patients with poor histologic differentiation (P = 0.001), lymph node metastasis (P < 0.001), and recurrence (P < 0.001) group was heightened. Using Kaplan�Meier analysis, a comparison of survival curves of low versus high expresser of ?5?1-integrin revealed a highly significant difference in human GC tissue (P = 0.002), which suggested that overexpression of ?5?1-integrin is associated with a worse prognosis. Multivariate analyses showed that ?5?1-integrin expression was independent risk factor predicting overall survival [Hazard ratio (HR) 1.594, 95 % confidence interval (CI) 1.236�2.408, P = 0.006] and disease-free survival [HR 3.952, 95 % CI 1.676�9.861, P = 0.003] in GC.

    Conclusions The ?5?1-integrin promotes angiogenesis and associates with lymph node metastasis, vascular invasion and poor prognosis of GC. The current study shows that ?5?1-integrin may be an independent prognostic factor for GC patients.